Nuevolution A/S

https://www.nuevolution.com

Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented speed and scale. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis, Boehringer Ingelheim and Cancer Research Technology, where Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered into licensing agreements with Nuevolution. Nuevolution has entered a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $4 million budgeted project is supported by the Danish High Technology Fund. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution. Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolutions internal programs are focused on therapeutically important targets within inflammation and oncology. Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences. *

	Start	2001-05-01 established
	Group	Nuevolution (Group)
	Industry	drug discovery services
	Industry 2	Chemetics® drug discovery technology
	Person	Gouliaev, Alex Haahr (Nuevolution 201205 CEO + Co-founder before NeuroSearch)
	Person 2	Simonsen, Henrik (Nuevolution 201509– CFO before Director Life Science at Corporate Finance at SEB)

	Region	København (Copenhagen)
	Country	Denmark
	Street	8 Rønnegade
	City	2100 Copenhagen
	Tel	+45-70-200987
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12